Rituximab for Nephrotic Syndrome in Children

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2016 Jul 17

PMID 27422620

Citations 42

Authors

Kazumoto Iijima

Mayumi Sako

Kandai Nozu

Affiliations

Soon will be listed here.

Abstract

Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children. At least 20 % of children with this syndrome show frequent relapses and/or steroid dependence during or after immunosuppressive therapies, a condition defined as complicated frequently relapsing/steroid-dependent nephrotic syndrome (FRNS/SDNS). Approximately 1-3 % of children with idiopathic nephrotic syndrome are resistant to steroids and all immunosuppressive agents, a condition defined as refractory steroid-resistant nephrotic syndrome (SRNS); these SRNS children have a high risk of end-stage renal failure. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be effective for patients with complicated FRNS/SDNS and refractory SRNS. This review describes the recent results of rituximab treatment applied to pediatric nephrotic syndrome, as well as those of our recent study, a multicenter, double-blind, randomized, placebo-controlled trial of rituximab for childhood-onset complicated FRNS/SDNS (RCRNS01). The overall efficacy and safety of rituximab for this disease are discussed.

Citing Articles

Single (375 mg/m) vs. double dose of rituximab along with mycophenolate mofetil for children with steroid-dependent/frequently relapsing nephrotic syndrome: a multicentre open-label randomized controlled trial.

Sinha R, Pradhan S, Raut S, Banerjee S, Sarkar S, Akhtar S Pediatr Nephrol. 2024; 40(4):995-1004.

PMID: 39729126 DOI: 10.1007/s00467-024-06619-8.

Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up.

Ivanov D, Weber L, Levtchenko E, Vakulenko L, Ivanova M, Zavalna I Biomedicines. 2024; 12(11).

PMID: 39595166 PMC: 11592163. DOI: 10.3390/biomedicines12112600.

Long Term Evaluations of First Single-dose Rituximab in Children with Steroid-Dependent Minimal-Change Nephrotic Syndrome.

Niu X, Gu Y, Feng D, Hao S, Kuang X, Wang P Ren Fail. 2024; 46(2):2427173.

PMID: 39593209 PMC: 11610296. DOI: 10.1080/0886022X.2024.2427173.

Rituximab versus tacrolimus as corticosteroid-sparing therapy for children with steroid-dependent nephrotic syndrome: A systematic review and meta-analysis of randomized and nonrandomized controlled trials.

Ang J, Widjanarko N, Ekaputra A Tzu Chi Med J. 2024; 36(3):319-329.

PMID: 38993828 PMC: 11236076. DOI: 10.4103/tcmj.tcmj_234_23.

Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: a multicenter study.

Yokota S, Kamei K, Fujinaga S, Hamada R, Inaba A, Nishi K Pediatr Nephrol. 2024; 39(10):2979-2988.

PMID: 38834892 DOI: 10.1007/s00467-024-06422-5.

References

. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978; 13(2):159-65. DOI: 10.1038/ki.1978.23. View

Chaumais M, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E . Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009; 24(9):1753-5. DOI: 10.1007/s00467-009-1195-9. View

Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M . Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009; 24(7):1321-8. DOI: 10.1007/s00467-009-1191-0. View

Basu B . Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014; 370(13):1268-70. DOI: 10.1056/NEJMc1308488. View

Tony H, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I . Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011; 13(3):R75. PMC: 3218885. DOI: 10.1186/ar3337. View

Ahn Y, Kang H, Lee J, Choi H, Ha I, Cheong H . Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol. 2014; 29(8):1461-4. DOI: 10.1007/s00467-014-2794-7. View

Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L . B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. J Am Soc Nephrol. 2015; 27(6):1811-22. PMC: 4884116. DOI: 10.1681/ASN.2015050523. View

Kamei K, Takahashi M, Fuyama M, Saida K, Machida H, Sato M . Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant. 2014; 30(1):91-6. DOI: 10.1093/ndt/gfu258. View

Bagga A, Sinha A, Moudgil A . Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007; 356(26):2751-2. DOI: 10.1056/NEJMc063706. View

10.

Kamei K, Okada M, Sato M, Fujimaru T, Ogura M, Nakayama M . Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2014; 29(7):1181-7. DOI: 10.1007/s00467-014-2765-z. View

11.

Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-LE Camus C, Afanetti M . Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23(8):1269-79. DOI: 10.1007/s00467-008-0814-1. View

12.

Le Berre L, Bruneau S, Naulet J, Renaudin K, Buzelin F, Usal C . Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol. 2008; 20(1):57-67. PMC: 2615726. DOI: 10.1681/ASN.2007111244. View

13.

Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y . Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010; 25(3):539-44. DOI: 10.1007/s00467-009-1377-5. View

14.

Sellier-Leclerc A, Belli E, Guerin V, Dorfmuller P, Deschenes G . Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol. 2013; 28(9):1875-9. DOI: 10.1007/s00467-013-2485-9. View

15.

Gulati A, Sinha A, Jordan S, Hari P, Dinda A, Sharma S . Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010; 5(12):2207-12. PMC: 2994081. DOI: 10.2215/CJN.03470410. View

16.

. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. 1981; 98(4):561-4. DOI: 10.1016/s0022-3476(81)80760-3. View

17.

Boren E, Cheema G, Naguwa S, Ansari A, Gershwin M . The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008; 30(1-2):90-8. DOI: 10.1016/j.jaut.2007.11.013. View

18.

Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H . Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 2002; 61(5):1801-5. DOI: 10.1046/j.1523-1755.2002.00303.x. View

19.

Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M . Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol. 2012; 28(2):257-64. DOI: 10.1007/s00467-012-2319-1. View

20.

Kemper M, Gellermann J, Habbig S, Krmar R, Dittrich K, Jungraithmayr T . Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2011; 27(5):1910-5. DOI: 10.1093/ndt/gfr548. View